Showing 4381-4390 of 5957 results for "".
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- RetinAI Launches Discovery CORE: AI Platform for Retinal Fluid and Layer Segmentationhttps://modernod.com/news/retinai-launches-discovery-core-ai-platform-for-retinal-fluid-and-layer-segmentation/2481269/RetinAI Medical AG has launched Discovery CORE with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and ima
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s
- Meivertor Single-Handed Upper and Lower Eyelid Eversion Tool Now Availablehttps://modernod.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/Introduced at the American Academy of Optometry meeting in San Diego, the Meivertor is designed to be a simple solution for an everyday challenge: eversion of the upper eyelid to image the meibomian glands. "Having images of the meibomian glands is important to
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Study: Form of AMD Strongly Associated With Cardiovascular Diseasehttps://modernod.com/news/study-blinding-eye-disease-strongly-associated-with-serious-forms-of-cardiovascular-disease/2481254/Patients with a specific form of age-related macular degeneration (AMD) are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study
- Sightpath Medical Acquires Accusite Surgicalhttps://modernod.com/news/sightpath-medical-acquires-accusite-surgical/2481253/Sightpath Medical announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Terms of the deal were not disclosed. Founded in 1991, Sightpath Medical delivers custom access to ophthalmic equipment, instruments, and services. Through its patented
- Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date for Pegcetacoplan for GAhttps://modernod.com/news/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-february-26-2023-for-pegcetacoplan-for-ga/2481252/Apellis Pharmaceuticals announced that the FDA has accepted Apellis’ unsolicited major amendment to the new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The updated Prescription D
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF